HMGB1 and non-small cell lung carcinoma: Naumnik et al. reported on elevated pretherapeutic levels of HMGB1 in 40 patients with NSCLC, but—possibly due to the low number of patients—there was no significant differentiation between stages IIIb und IV nor any prognostic information obtained by HMGB1 [37].